Search

Displaying results 7511 - 7520 of 7654 in total
  1. Drug

    OT-551

    go.drugbank.com/drugs/DB05650
    Investigational

    OT-551 is a novel small molecule that is topically dosed in an eye drop and has the unique ability to penetrate cell membranes and reach both the front and the back of the eye.

  2. Drug

    MVA-BN-brachyury-TRICOM vaccine

    go.drugbank.com/drugs/DB17424
    Investigational

    MVA-BN-brachyury-TRICOM vaccine is an investigational cancer vaccine.

  3. Drug

    Mivebresib

    go.drugbank.com/drugs/DB21300
    Investigational

    Mivebresib has a monoisotopic molecular weight of 459.11 Da.

  4. Drug

    CT-011

    go.drugbank.com/drugs/DB05916
    Investigational

    CT-011 is a humanized monoclonal antibody directed against a B7 family-associated protein, in patients with advanced haematological malignancies. It is directed against human PD-1 (programmed cell death 1; PDCD1), with immunomodulating a...

  5. Drug

    AX200

    go.drugbank.com/drugs/DB05093
    Investigational

    AX200, which has been developed for the treatment of stroke, is the most advanced drug candidate and is halfway through the process of gaining clinical approval. The expression of the endogenous AX200 protein in the brain is increased af...

  6. Drug

    C31G

    go.drugbank.com/drugs/DB05398
    Investigational

    C31G is a potent broad spectrum antimicrobial agent, effective against gram positive and gram negative bacteria, yeast and fungi.C31G, vaginal gel is developed by Biosyn Inc. and has commenced enrollment in a phase III pivotal clinical t...

  7. Drug

    Vicadrostat

    go.drugbank.com/drugs/DB21693
    Investigational

    Vicadrostat has a monoisotopic molecular weight of 317.06 Da.

  8. Drug

    Nizubaglustat

    go.drugbank.com/drugs/DB21603
    Investigational

    Nizubaglustat has a monoisotopic molecular weight of 433.23 Da.

  9. Drug

    Ad5-nCoV

    go.drugbank.com/drugs/DB15655
    Investigational

    being developed by CanSino Biologics Inc., in partnership with the Beijing Institute of Biotechnology, who in March 2020 announced the approval of a phase I clinical trial (ChiCTR2000030906)[L12675] with an

  10. Drug

    AV-COVID-19

    go.drugbank.com/drugs/DB15802
    Investigational

    As of July 2020, the company is pursuing an adaptive Phase IB-II Randomized Clinical Trial (NCT04386252) to test the vaccine.

    Synonyms: DC-ATA